Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naive and TNF-inadequate responder patients with psoriatic arthritis

A. M. Orbai, D. D. Gladman, H. Goto, J. A. Birt, A. M. Gellett, C. Y. Lin, T. K. Kvien

Research output: Contribution to journalArticlepeer-review

Abstract

Objective To analyse the onset and sustainability of patient-reported improvements in symptoms of psoriatic arthritis (PsA) following treatment with ixekizumab (IXE) up to Week 108. Methods In patients with active PsA, either naive to biological DMARDs (SPIRIT-P1) or having inadequate response or intolerance to 1 or 2 prior TNF-inhibitors (TNFi-experienced; SPIRIT-P2), we analysed the change from baseline in joint pain visual analogue scale (VAS; 0–100 scale), patient global assessment (PatGA VAS; 0–100 scale), fatigue numerical rating scale (NRS; 0 [no fatigue] to 10 [worst imaginable]), and Health Assessment Questionnaire-Disability Index (HAQ-DI; 0–3), up to Week 108. Results IXE-treated patients compared to placebo reported rapid and statistically significant improvement in pain VAS, PatGA, and HAQ-DI as early as Week 1 and this benefit was sustained or increased through Week 108. Fatigue scores improved in IXE-treated patients compared to placebo in both studies; results were statistically significant at Week 24 only in SPIRIT-P2. Improvements in fatigue with IXE were sustained over 2 years. The improvements observed in these patient-reported outcomes (PROs) were consistent in biologic-naive or TNFi-experienced patients. Conclusion Patients treated with IXE versus PBO achieved significantly greater improvements and showed faster onset of improvements in patient-reported outcomes measuring symptoms and impact of PsA. Responses were sustained over 2 years and were generally consistent regardless of prior TNFi experience.

Original languageEnglish (US)
Pages (from-to)329-336
Number of pages8
JournalClinical and experimental rheumatology
Volume39
Issue number2
StatePublished - Mar 2021

Keywords

  • Anti-IL-17
  • Fatigue
  • Ixekizumab
  • Pain
  • Patient-reported outcomes
  • TNF-inhibitors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Fingerprint

Dive into the research topics of 'Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naive and TNF-inadequate responder patients with psoriatic arthritis'. Together they form a unique fingerprint.

Cite this